Trials / Completed
CompletedNCT05303740
Anlotinib Retrospective Study for Esophageal Cancer
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Feng Wang · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | This is an observational study. |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
- First posted
- 2022-03-31
- Last updated
- 2022-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05303740. Inclusion in this directory is not an endorsement.